Treatment of metastatic ovarian cancer, non–small-cell lung cancer; second-line treatment for AIDS-related Kaposi’s sarcoma (KS); adjuvant treatment of node-positive breast cancer sequential to a course of standard doxorubicin-containing combination chemotherapy
Paliperidone ER uses the osmotic drug-release technology that delivers the drug at a controlled rate. Oral bioavailability of paliperidone ER is 28%. Protein binding: 74%. Paliperidone dissolves slowly following IM injection. Not extensively metabolized in the liver. Extensively excreted in the kidney unchanged; minimal in feces. Half-life: 23 hr (PO); 25–49 days (IM).
• Physician should be informed if significant xerostomic side effects occur (e.g., increased caries, sore tongue, problems eating or swallowing, difficulty wearing prosthesis) so that medication change can be considered.
Treatment of moderate-to-severe Paget’s disease, mild-to-moderate hypercalcemia associated with malignancy with or without bone metastases, osteolytic bone metastases in breast cancer, multiple myeloma patients
A pancreatic digestive enzyme combination (protease, lipase, amylase) that hydrolyzes fats to glycerol and fatty acids, converts proteins into peptides and amino acids, and converts starch into dextrins and maltose.
Enzyme replacement therapy for pancreatic insufficiency, such as in cystic fibrosis, chronic pancreatitis, post-pancreatectomy, ductal obstructions causes by pancreatic or bile duct tumors, steatorrhea of malabsorption, and post-gastrectomy.
Locally inactivated in the GI tract by anti-enzymes, excreted by the intestinal mucosa, or by the action of protease enzymes. Digested enzyme fragments may be absorbed by blood and are excreted in urine, or excreted in feces.
An antineoplastic agent that binds specifically to epidermal growth factor (EGFR) on normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Blocks phosphorylation and activation of intracellular tyrosine kinases, resulting in inhibition of cell survival, growth, proliferation, and transformation.
Treatment may be resumed at 50% of the original dose. If toxicities recur, permanently discontinue drug. If toxicities do not recur, subsequent doses may be increased in increments of 25% of the original dose until the recommended dose of 6 mg/kg is obtained.
Dermatologic toxicity, erythema, acneiform rash, pruritus, hypomagnesemia, fatigue, exfoliation, abdominal pain, paronychia, nausea, rash, diarrhea, constipation, fissures, vomiting, cough, acne, peripheral edema, dry skin
A benzimidazole that is converted to active metabolites that irreversibly bind to and inhibit hydrogen-potassium adenosine triphosphate, an enzyme on the surface of gastric parietal cells. Inhibits hydrogen ion transport into gastric lumen.
Rapidly absorbed from the GI tract. Protein binding: 98%. Primarily distributed into gastric parietal cells. Metabolized extensively in the liver. Primarily excreted in urine. Not removed by hemodialysis. Half-life: 1 hr.
Caution is warranted with a chronic or current hepatic disease. It is unknown if pantoprazole crosses the placenta or is distributed in breast milk. Safety and efficacy of pantoprazole have not been established in children. No age-related precautions have been noted in the elderly. Serum chemistry laboratory values, including serum creatinine and cholesterol levels, should be obtained before therapy.
Treatment of arterial spasm resulting in cerebral and peripheral ischemia; myocardial ischemia associated with vascular spasm or dysrhythmias; angina pectoris; peripheral pulmonary embolism; visceral spasm as in ureteral, biliary, and GI colic PVD; unapproved: with phentolamine or alprostadil for intracavernous injection for impotence
Injection: General discomfort, nausea, abdominal discomfort, anorexia, constipation, diarrhea, skin rash, malaise, vertigo, headache, intensive flushing of the face, perspiration, increased depth of respiration, increased heart rate, slight rise in B/P, excessive sedation
Variably absorbed from the GI tract. Protein binding: low. Metabolized in liver. Primarily excreted in urine primarily as morphine glucuronide conjugates and unchanged drug—morphine, codeine, papaverine, etc. Unknown if removed by hemodialysis. Half-life: 2–3 hr.
Paradoxical excitement, confusion, pounding heartbeat, facial flushing, decreased urination, blurred vision, dizziness, dry mouth, headache, hypotension, decreased appetite, redness, burning, pain at injection site
! Overdosage results in cold or clammy skin, confusion, convulsions, decreased B/P, restlessness, pinpoint pupils, bradycardia, respiratory depression, decreased level of consciousness, and severe weakness.